Improved Muscle Metabolism by Combination of Muscle Activation and Protein Substitution ( IMEMPRO )
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Dietary Supplement: additional substitution of protein, Neuromuscular electrical stimulation, Early Mobilization.
- Who it may be relevant to
- Registry conditions: ICU Acquired Weakness, Muscle Atrophy, Energy Malnutrition Protein, Quality of Life. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Austria, Germany
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Improved Muscle Metabolism by Combination of Muscle Activation and Protein Substitution: a Randomized, Outcome-assessor Blinded, Proof-of-concept Study (IMEMPRO)
Overview
Intensive Care Unit Acquired Weakness (ICUAW) describes muscle weakness that occurs in around 40% of patients during an intensive care stay. The morbidity and mortality of these patients is significantly increased over a 5-year period. The aim of this study is to investigate the combined effect of early enteral high-protein nutrition and early muscle activation on muscle atrophy in critically ill patients. The study will include 40 patients (20 intervention, 20 observation) with requirement for enteral nutrition at time of inclusion. In the intervention group the maximum possible level of mobilization is carried out and muscles are activated twice a day using neuromuscular electrical stimulation (NMES). The nutrition plan of the intervention group is based on the applicable guidelines for intensive care medicine with exception of increased protein intake. The control group receives therapy without deviating from the standard according of the DGEM guideline. The study aims to show that the decrease in muscle mass is significantly less than in the control group (primary hypothesis) via ultrasound of the rectus femoris muscle and in case of given consent muscle biopsy. As secondary hypothesis it is examined whether the combination of early high protein intake and muscle activation improves muscle strength and endurance.
Detailed description
Intensive Care Unit Acquired Weakness (ICUAW) describes the clinically diagnosed manifestation of a neuromuscular organ dysfunction. It develops in approximately 40% of all intensive care unit patients amounting to at least 1.2 million patients annually in Germany. All these patients face a broad range of sequeleae and an increased mortality up to 5 years after ICU discharge. A characteristic pathophysiological phenomenon is an early severe muscle atrophy reaching 10% during the first days after ICU admission.
The current preventative and therapeutic approach for ICUAW is a combination of targeted risk factor management as well as early activation of muscles, i.e. neuromuscular electrical stimulation (NMES) and early mobilization as they have been shown to counteract the muscle atrophy and mediate different outcome benefits such as shorter ICU stay.
Nutrition is a key element of our daily life. Protein intake has been shown to affect lean mass and muscle mass. Research into specific nutritional strategies to treat or prevent ICUAW are scarce and the combination with early muscle activation has not been adequately explored.
The study will include 40 patients (20 intervention, 20 observation) who were admitted to an intensive care unit within the last 48 hours. A basic requirement for inclusion is an indication for enteral (via the gastrointestinal tract) nutrition at time of inclusion. In the intervention group, the ability to mobilize is assessed daily and the maximum possible level of mobilization is carried out and additional muscles are activated twice a day using neuromuscular electrical stimulation (NMES). The nutrition plan of the intervention group is based on the applicable guidelines for intensive care medicine. In this study, protein intake is increased in the interventional group. The control group receives therapy without deviating from the standard according to the SOP and DGEM guideline: "Clinical nutrition in intensive care medicine" 2018.
The study aims to show that the decrease in muscle mass is significantly less than in the control group (primary hypothesis) via ultrasound of the rectus femoris muscle and muscle biopsy. As a second hypothesis it is examined whether the combination of early high protein intake and muscle activation improves muscle strength and endurance compared to the control group.
Further exploratory analyses will investigate changes in the skeletal muscle glycogen content, skeletal muscle histology, skeletal muscle gene expression, skeletal muscle protein level, as well as metabolomic changes in blood and urine.
An additional blood sample will be taken after 90 days as part of a follow-up.
Interventions
- Dietary supplement Dietary Supplement: additional substitution of protein
Day one (admission) no nutrition is applied. Protein target is increased as follows: * to a level of 1,2g/kg/d on day 1 after ICU admission * to a level of 1,4g/kg/d on day 2 after ICU admission * to a level of 1,6g/kg/d on day 3 after ICU admission * to a level of 1,8g/kg/d on day 4 after ICU admission * to a level of 2,0g/kg/d from day 5 onwoards Additional protein is given within 2 hours after mobilization respectively: * to 0,125g/kg/d on day 1 after ICU admission * to 0,2g/kg/d on day 2 - Device Neuromuscular electrical stimulation
twice daily 60 minutes till day 28 or ICU discharge - Other Early Mobilization
at least 20 minutes a day following the SOMS concept. Duration: till 28 day or ICU discharge
Primary outcome measures
- Change in cross sectional area (ΔCSA) of the rectus femoris [Time frame: day 1 (study inclusion) and 14 days]
Secondary outcome measures (12)
- change in muscle thickness of the rectus femoris [Time frame: day 1 (study inclusion) until 90-day Follow-up]
- change in echogenicity of the rectus femoris [Time frame: day 1 (study inclusion) until 90-day Follow-up]
- change of the pennation angle of the rectus femoris [Time frame: day 1 (study inclusion) until 90-day Follow-up]
- change of the muscle strength, measured by the Medical Research Council score (MRC-score) [Time frame: day 1 (study inclusion) until 90-day Follow-up]
- change of the muscle strength, measured by handgrip dynamometry [Time frame: day 1 (study inclusion) until 90-day Follow-up]
- change in muscle endurance [Time frame: up to 90 day follow up]
- change in physical physical function [Time frame: up to 90-day follow-up]
- development of quality of life [Time frame: up to 90-day follow-up]
- change in Skeletal muscle mass [Time frame: day 1 (study inclusion) until 90-day Follow-up]
- change in extracellular volume [Time frame: day 1 (study inclusion) until 90-day Follow-up]
- change in the REE (Resting Energy Expenditure) [Time frame: day 1 (study inclusion) until 90-day Follow-up]
- urea-to-creatinine ratio [Time frame: day 1 (study inclusion) until 90-day Follow-up]
Eligibility criteria
Inclusion criteria
- critically ill adults (≥ 18 years of age)
- newly admitted to the ICU (<48h)
- mechanically ventilated, expected to remain for at least 72h
- enteral nutrition is feasible
Exclusion criteria
- a BMI > 30
- expected death or withdrawal of life-sustaining treatments
- prior neuromuscular disease (e.g. paresis, myopathies, neuropathies)
- injury or disease preventing neuromuscular electrical stimulation or early mobilization (e.g., elevated intracranial pressure, unstable spine)
- a pacemaker or other electronic implant
- allergy to components of NMES adhesive
- have been dependent during activities of daily living prior to the hospital admission
- a language barrier
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Prevention
Study locations
Germany · 3 centers
- Klinikum rechts der Isar, School of Medicine, Technical Universtity of Munich — Munich
- Charité - Universitätsmedizin Berlin — Berlin
- Universitätsklinikum Ulm — Ulm
Austria · 1 center
- Medical University of Vienna — Vienna
Identifiers
NCT: NCT05919940 · IMEMPRO